The goal of this clinical trial is to evaluate the safety of arterial embolization using Lipiodol® in patients with symptomatic hand osteoarthritis refractory to conventional treatment. It will also learn about the efficacy of arterial embolization with Lipiodol® in reducing pain and improving hand function.
The main questions it aims to answer are:
* What are the side effects and complications associated with the Lipiodol® arterial embolization procedure? * Does arterial embolization reduce pain intensity and improve hand function?
Researchers will evaluate patients over a 6-month period to assess the safety of Lipiodol® embolization and its impact on joint pain, swelling, and functional capacity. Participants will:
* Undergo arterial embolization with Lipiodol® * Participate in regular follow-ups to monitor pain relief, hand function, and any side effects * Have imaging studies to assess changes in joint vascularisation and damage
Patients aged ≥ 40 years.
Osteoarthritis of the hand according to American College of Rheumatology criteria 1990
Osteoarthritis affecting at least two proximal and/or distal interphalangeal joints with a radiological Kellgren-Lawrence stage ≥ 2.
Symptomatic osteoarthritis within the last 3 months.
History of allergy to iodinated contrast media, LipiodolⓇ or poppies.
Vasomotor disorders (Raynaud's syndrome, scleroderma, acrocyanosis).
Stenosis (>50%) or known atheromatous arterial occlusion of the upper limbs.
Obliterative arterial disease of the lower limbs at the critical ischaemia stage.
University Hospital, Grenoble
Lead sponsor